News

Su Radio Fantastica è intervenuto il Prof. Francesco Pappalardo docente di Informatica dell'Università degli Studi di Catania.

Ascolta l'intervista su YouTube: https://youtu.be/DIbDib6JmZA

Today the COMBINE group releases as open-source (under Apache License v2.0) the main core of UISS in silico trial platform.

You can find the source code following this link: https://www.combine-group.org/assets/attachment/UISS_free.tgz

Antibodies therapeutics are unable to protect patients with severe SARS-CoV-2 infection. This is the study conclusion by the COMBINE group of the University of Catania and published in the prestigious scientific journal BMC Bioinformatics. 

"The study had been carried out during the COVID-19 emergency in the spring of last year and…

A seminar entitled "Come nasce un farmaco" will be held on November 26, 2020 from 4 to 4.30 pm.

Link to join on MS Teams: https://www.sharper-night.it/evento/conferenza-come-nasce-un-farmaco/
Code for join: i7qdx35

Official Site: https://www.sharper-night.it/

#sharpernight #sharpernightcatania #insilico #insilicotrials #insilicomedicine #combinegroup

A seminar entitled "Università Imprenditoriale" will be held on November 23, 2020 from 10.30 to 11.45 am.

Event link: https://www.sharper-night.it/evento/conferenza-universita-imprenditoriale/

Official Site: https://www.sharper-night.it/

#sharpernight #sharpernightcatania #insilico #insilicotrials #insilicomedicine #combinegroup

The overall aim of the In Silico World project is to accelerate the uptake of modelling and simulation technologies for the development and regulatory assessment of all kind of medical products.

This will be achieved by supporting the trajectory of a number of In Silico Trials solutions through development, validation, regulatory…

Evitare, o ridurre al lumicino, la sperimentazione sugli animali; accelerare il processo di approvazione dei farmaci e scansare i vicoli ciechi nella ricerca.
Sono questi gli obiettivi cui punta un gruppo di ricercatori dell'Università di Catania con Uiss, il paziente virtuale. Uiss sta per Universal Immune System Simulator, è frutto…

To promptly and rapidly respond to pandemic events, the application of in silico trials can be used for designing and testing medicines against SARS-CoV-2 and speed-up the vaccine discovery pipeline, predicting any therapeutic failure and minimizing undesired effects. We just released (and submitted for possible consideration in one of the…

COMBINE Group (University of Catania) is one of the partner of 3TR project, the largest-ever Innovative Medicine Initiative 2 (IMI2) immunology project to improve disease management of non-responders to therapy across seven immune-mediated diseases.

Read on: Full Description of 3TR and See the video

Maintaining European scientific excellence and global leadership in TB Vaccine R&D

Document Link

Another important milestone has been reached by the STriTuVaD project in these days.

The team of the University of Catania (Italy) successfully extended their modeling framework in order to include dynamics and specific features of…

STriTuVaD consortium meeting lays down the foundations for a fruitful EU-India cooperation in the fight against Tuberculosis

Document Link

STriTuVaD consortium plan its regulatory strategy.

#STriTuVaD #insilicotrials #EMA #UISS #regulatoryqualification

Document Link

Can new drugs be tested with computers? EU-funded team explores the future of tuberculosis drugs testing.

#insilicotrials, #StriTuVad, #tuberculosis, #UniCT, #COMBINE

Read more...

The most important financial newspaper in Italy recently published an article about the scientific coordination  of the COMBINE Group in the EC Horizon 2020 funded project STriTuVaD.

Friday, 16 March 2018

On February 1, STriTuVaD project officially started.

The StriTuVaD multidisciplinary consortium, will deliver an in silico trial platform to simulate the relevant individual human physiology and physiopathology in patients affected by Mycobacterium tuberculosis. Virtual populations of individuals (a set of libraries of virtual patients for re-use in…